EXON 21 MUTATION P471L D350G C420R N345K E545X H1047X OVEREXPRESSION R93W K111N I391M D549N S158L E81K G1049A R1023Q EXON 20 MUTATION EXON 9 MUTATION PIK3CA 基因突变 EXON 20 MUTATION Allele Registry ID:别名: ClinVar ID: 基因突变位点 Ref. Build: Ensembl Version: null Chr. Start...
5.TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically-relevant EGFR mutations 免责声明 “药渡”公众号所转载该篇文章来源于其他公众号平台,...
HER2 exon 20 mutationintracranial metastasesnon-small cell lung cancertrastuzumab deruxtecan.Trastuzumab deruxtecan (T-DXd) is a novel anti-HER2 antibody-drug conjugate formed by the combination of trastuzumab and deruxtecan. It is used in human epidermal growth factor 2 receptor (HER2) mutant ...
3.Yasuda H, Ichihara E, Sakakibara-Konishi J, et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140-146. doi:10.1016/j.lungcan.2021.10.006. 4.Girard N. WCLC 2020. Abstract MA04.07. 5.Yang G, Li...
《柳叶刀·呼吸医学》(The Lancet Respiratory Medicine,IF=76.2)发表题为“Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial”的...
Metro 等的研究结果显示,接受免疫治疗的 EGFR ex20ins 突变型晚期 NSCLC 患者中位 PFS 为 2 个月,中位 OS 为 5.3 个月,免疫治疗的效果欠佳。推测其原因可能是由于 EGFR ex20ins 突变型 NSCLC 患者的肿瘤突变负荷(tumor mutation burden,TMB)显著低于非 EGFR ex20ins 突变型 NSCLC 患者,且 EGFR ex20ins ...
Distribution of EGFR mutations and EGFR exon 20 mutation types and EGFRex20ins in this study.a. Distribution of EGFR mutations.b. Distribution of EGFR exon 20 mutation types and EGFRex20ins mutations Full size image In total, 20 different variants of exon EGFRex20ins were identified in 53 ...
We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment.关键词: Osimertinib EGFR exon 20 mutation Non-small cell lung cancer DOI: 10.1016/j.lungcan.2019.12.013 年份: 2020 ...
Although almost all common EGFR mutations, such as exon 19 deletions and the L858R point mutation in exon 21, are sensitive to EGFR-tyrosine kinase inhibitor (TKI) therapies, NSCLC driven by EGFR exon 20 insertion mutations is associated with poor clinical outcomes due to dose-limiting toxicity,...
et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. Eur. J. Cancer https://doi.org/10.1016/j.ejca.2021.02.038 (2021). Le, X. et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion ...